BRAF and glycogen storage disease VI: Among patients with BRAF-mutant melanoma and brain metastases (MBM), treatment with the BRAF inhibitors dabrafenib or vemurafenib leads to response rates of 20% and 38%, respectively, in patients with radiotherapy-naïve disease [21, 22].